NASDAQ:ETNB 89bio (ETNB) Stock Price, News & Analysis $9.24 -0.42 (-4.35%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$9.19▼$9.8550-Day Range$7.31▼$9.6652-Week Range$6.57▼$18.30Volume628,599 shsAverage Volume1.12 million shsMarket Capitalization$909.03 millionP/E RatioN/ADividend YieldN/APrice Target$26.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get 89bio alerts: Email Address 89bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside188.6% Upside$26.67 Price TargetShort InterestBearish6.26% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.19Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.42) to ($3.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.11 out of 5 starsMedical Sector811th out of 936 stocksPharmaceutical Preparations Industry377th out of 436 stocks 3.4 Analyst's Opinion Consensus Rating89bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst Coverage89bio has only been the subject of 3 research reports in the past 90 days.Read more about 89bio's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.26% of the outstanding shares of 89bio have been sold short.Short Interest Ratio / Days to Cover89bio has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in 89bio has recently decreased by 4.05%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend Yield89bio does not currently pay a dividend.Dividend Growth89bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ETNB. Previous Next 2.9 News and Social Media Coverage News Sentiment89bio has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for 89bio this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ETNB on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added 89bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 89bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.80% of the stock of 89bio is held by insiders.Read more about 89bio's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for 89bio are expected to decrease in the coming year, from ($2.42) to ($3.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 89bio is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 89bio is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio89bio has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about 89bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About 89bio Stock (NASDAQ:ETNB)89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Read More ETNB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ETNB Stock News HeadlinesJuly 18, 2024 | americanbankingnews.com89bio (NASDAQ:ETNB) Shares Gap Up to $9.00July 12, 2024 | globenewswire.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 27, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."June 14, 2024 | globenewswire.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 23, 2024 | seekingalpha.com89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong BuyMay 22, 2024 | globenewswire.com89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver CongressMay 16, 2024 | markets.businessinsider.comBuy Rating for 89bio on Pegozafermin’s Promise in Advanced NASH TrialsMay 15, 2024 | morningstar.com89bio Inc Ordinary SharesJuly 27, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."May 14, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Hold Rating on 89bio (ETNB)May 14, 2024 | globenewswire.com89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated CirrhosisMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for 89bio Amid Pegozafermin’s Clinical Advances and Market PotentialMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for 89bio Amid Promising Drug Candidate Progress and Strategic ReadinessMay 10, 2024 | finance.yahoo.com89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical TrialsMay 10, 2024 | globenewswire.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 9, 2024 | msn.comETNB Stock Earnings: 89bio Misses EPS for Q1 2024May 9, 2024 | globenewswire.com89bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | globenewswire.com89bio to Participate in the BofA Securities 2024 Health Care ConferenceSee More Headlines Receive ETNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ETNB CUSIPN/A CIK1785173 Webwww.89bio.com Phone415-432-9270FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$26.67 High Stock Price Target$33.00 Low Stock Price Target$14.00 Potential Upside/Downside+187.4%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-142,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-34.76% Return on Assets-31.05% Debt Debt-to-Equity Ratio0.05 Current Ratio15.03 Quick Ratio15.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.75 per share Price / Book1.61Miscellaneous Outstanding Shares98,380,000Free Float95,629,000Market Cap$912.97 million OptionableOptionable Beta1.10 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Rohan Palekar (Age 58)CEO & Director Comp: $1.06MMr. Quoc Le-Nguyen (Age 56)Chief Technical Operations Officer Comp: $702.87kDr. Harry Mansbach M.D. (Age 59)Chief Medical Officer Comp: $732.87kMr. Ryan Stephen Martins (Age 45)Chief Financial Officer Mr. Shiva K. Natarajan CPA (Age 58)Senior Vice President of Finance & Principal Accounting Officer Ms. Annie J. Chang M.B.A.VP of Investor Relations & Corporate CommunicationsMs. Amanda KuriharaVice President of People & CultureMs. Melissa AbelSenior Vice President of Commercial StrategyMr. Paul ShinSenior Vice President of R&D OperationsMr. Michael BaldwinVP & Head of QualityMore ExecutivesKey CompetitorsIntercept PharmaceuticalsNASDAQ:ICPTAlbireo PharmaNASDAQ:ALBOTG TherapeuticsNASDAQ:TGTXMerusNASDAQ:MRUSXenon PharmaceuticalsNASDAQ:XENEView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 50,943 shares on 7/26/2024Ownership: 0.305%Raymond James & AssociatesBought 47,670 shares on 7/19/2024Ownership: 0.186%SG Americas Securities LLCBought 25,292 shares on 7/12/2024Ownership: 0.026%Harbor Capital Advisors Inc.Bought 61,641 shares on 7/9/2024Ownership: 0.087%Comerica BankBought 15,070 shares on 5/17/2024Ownership: 0.174%View All Insider TransactionsView All Institutional Transactions ETNB Stock Analysis - Frequently Asked Questions How have ETNB shares performed this year? 89bio's stock was trading at $11.17 on January 1st, 2024. Since then, ETNB shares have decreased by 17.3% and is now trading at $9.24. View the best growth stocks for 2024 here. How were 89bio's earnings last quarter? 89bio, Inc. (NASDAQ:ETNB) posted its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by $0.08. When did 89bio IPO? 89bio (ETNB) raised $70 million in an initial public offering on the week of November 11th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager. Who are 89bio's major shareholders? 89bio's top institutional shareholders include Bank of New York Mellon Corp (0.30%), Raymond James & Associates (0.19%), Harbor Capital Advisors Inc. (0.09%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Ra Capital Management, LP, Rohan Palekar, Quoc Le-Nguyen, Ryan Martins, Orbimed Advisors Llc, Kathleen Laporte and Ram Waisbourd. View institutional ownership trends. How do I buy shares of 89bio? Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of 89bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), RTX (RTX), Alibaba Group (BABA) and Procter & Gamble (PG). This page (NASDAQ:ETNB) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 89bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
